Haifeng Chen

Haifeng Chen has worked in the biotechnology industry since 1997. Theirfirst position was as a Senior Scientist at Genovo from 1997 to 1996. During this time, they were in charge of projects for creating recombinant adenovirus that carries human interferon b gene and establising stable E-1 expressing cell line to complement E1-deleted adenovirus. Haifeng also completed the project of generating recombinant adenovirus carrying AAV rep/cap genes for AAV production and filed patent, as well as the project of generating recombinant baculovirus carrying adenovirus helper genes and AAV rep/cap genes for AAV production and filed patent. From 1996 to 2000, they worked as a Research Scientist IV at Avigen, Inc. During this time, they successfully established a scalable baculovirus system for recombinant adeno-associated virus (rAAV) vector production at 25-liter scale, purified large amounts of rAAV vectors using column chromatography for preclinical studies of hemophilia and Gaucher gene therapies, and cloned more than two hundreds of different plasmid constructs for the company’s various gene therapy projects. From 2005 to 2019, they worked at Asklepois BioPharmaceutical, Inc. as a VP. During this time, they also served as a Consultant for Virovek, Inc. from 2006 to 2019, and as Vice President/Chief Scientific Officer and CEO from 2006 to 2019. In 2019, they joined Avirmax, Inc. as Chief Scientific Officer.

Haifeng Chen received their Bachelor of Science in Biology from Sun Yat-sen University between 1978 and 1982. Haifeng then went on to earn their Master in Plant Genetics from Sichuan University between 1982 and 1985. Finally, they completed their PH.D in Virology from Universität des Saarlandes between 1989 and 1992.